All AbMole products are for research use only, cannot be used for human consumption.
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multireceptor tyrosine kinases (RTKs), including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM and 7.2 nM in cell analysis, respectively. XL092 has antitumor activity.
| Molecular Weight | 528.53 |
| Formula | C29H25FN4O5 |
| CAS Number | 2367004-54-2 |
| Form | Solid |
| Solubility (25°C) | DMSO 11 mg/mL |
| Storage | 4°C, protect from light |
| Related TAM Receptor Products |
|---|
| UNC1062
UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. |
| AZ14145845
AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy. |
| Axl/Mer/CSF1R-IN-2
Axl/Mer/CSF1R-IN-2 is a Axl, Mer and CSF1R inhibitor. |
| AXL-IN-15
AXL-IN-15 is a potent Axl inhibitor with both Ki and IC50 <1 nM. |
| Glesatinib
Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
